Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Dodges Chance To Impose Linkage And Exclusivity

Executive Summary

Patent-linkage and data exclusivity changes have not been implemented in a major overhaul of medicines law in China. But they could still come through patent law updates.

You may also be interested in...



China's New Pharma Law Leaves Key Questions Unanswered

Much anticipated legislation signals flexibility over online sales of pharma products and definition of counterfeits, but the law also falls short on key elements of pharmaceutical innovation and intellectual property rights protection, says one legal expert.

China Releases List To Encourage Competition

China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.

German Fund Seeks Security By Choosing Several Suppliers

By sharing 80% of its tender contracts to multiple suppliers, German insurance fund Barmer is aiming to mitigate the risk of medicines shortages.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel